135 related articles for article (PubMed ID: 3051072)
1. Social functioning in chronic depression: effect of 6 weeks of antidepressant treatment.
Stewart JW; Quitkin FM; McGrath PJ; Rabkin JG; Markowitz JS; Tricamo E; Klein DF
Psychiatry Res; 1988 Aug; 25(2):213-22. PubMed ID: 3051072
[TBL] [Abstract][Full Text] [Related]
2. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression.
McGrath PJ; Stewart JW; Nunes EV; Ocepek-Welikson K; Rabkin JG; Quitkin FM; Klein DF
Am J Psychiatry; 1993 Jan; 150(1):118-23. PubMed ID: 8417553
[TBL] [Abstract][Full Text] [Related]
3. Chronic depression: response to placebo, imipramine, and phenelzine.
Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E
J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152
[TBL] [Abstract][Full Text] [Related]
4. Double-blind study of imipramine versus phenelzine in Melancholias and Dysthymic Disorders.
Vallejo J; Gasto C; Catalan R; Salamero M
Br J Psychiatry; 1987 Nov; 151():639-42. PubMed ID: 3446308
[TBL] [Abstract][Full Text] [Related]
5. A comparison of phenelzine and imipramine in depressed inpatients.
Davidson JR; McLeod MN; Turnbull CD; Miller RD
J Clin Psychiatry; 1981 Oct; 42(10):395-7. PubMed ID: 7026542
[TBL] [Abstract][Full Text] [Related]
6. Relevance of DMS-III depressive subtype and chronicity of antidepressant efficacy in atypical depression. Differential response to phenelzine, imipramine, and placebo.
Stewart JW; McGrath PJ; Quitkin FM; Harrison W; Markowitz J; Wager S; Leibowitz MR
Arch Gen Psychiatry; 1989 Dec; 46(12):1080-7. PubMed ID: 2686575
[TBL] [Abstract][Full Text] [Related]
7. Tyramine sulfate excretion may be a better predictor of antidepressant response than monoamine oxidase activity.
Stewart JW; Harrison W; Cooper TB; Quitkin FM
Psychiatry Res; 1988 Aug; 25(2):195-201. PubMed ID: 3051071
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission.
Stewart JW; Tricamo E; McGrath PJ; Quitkin FM
Am J Psychiatry; 1997 Jan; 154(1):31-6. PubMed ID: 8988955
[TBL] [Abstract][Full Text] [Related]
9. Life satisfaction and psychosocial functioning in chronic depression: effect of acute treatment with antidepressants.
Agosti V; Stewart JW; Quitkin FM
J Affect Disord; 1991 Sep; 23(1):35-41. PubMed ID: 1774421
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant specificity in atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
[TBL] [Abstract][Full Text] [Related]
11. Phenelzine v imipramine in atypical depression. A preliminary report.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF
Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621
[TBL] [Abstract][Full Text] [Related]
12. Response to phenelzine and imipramine in placebo nonresponders with atypical depression. A new application of the crossover design.
Quitkin FM; Harrison W; Stewart JW; McGrath PJ; Tricamo E; Ocepek-Welikson K; Rabkin JG; Wager SG; Nunes E; Klein DF
Arch Gen Psychiatry; 1991 Apr; 48(4):319-23. PubMed ID: 2009033
[TBL] [Abstract][Full Text] [Related]
13. An outpatient evaluation of phenelzine and imipramine.
Davidson J; Raft D; Pelton S
J Clin Psychiatry; 1987 Apr; 48(4):143-6. PubMed ID: 3549705
[TBL] [Abstract][Full Text] [Related]
14. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders.
Quitkin FM; Stewart JW; McGrath PJ; Liebowitz MR; Harrison WM; Tricamo E; Klein DF; Rabkin JG; Markowitz JS; Wager SG
Am J Psychiatry; 1988 Mar; 145(3):306-11. PubMed ID: 3278631
[TBL] [Abstract][Full Text] [Related]
15. Phenelzine for chronic depression: a study of continuation treatment.
Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F
J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558
[TBL] [Abstract][Full Text] [Related]
16. Psychopharmacologic validation of atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin JG; Tricamo E; Markowitz JS; Klein DF
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):22-5. PubMed ID: 6376483
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
18. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine.
Rabkin JG; Markowitz JS; Stewart J; McGrath P; Harrison W; Quitkin FM; Klein DF
Psychiatry Res; 1986 Sep; 19(1):75-86. PubMed ID: 3538107
[TBL] [Abstract][Full Text] [Related]
19. Plasma melatonin levels in depressed patients before and after treatment with antidepressant medication.
Stewart JW; Halbreich U
Biol Psychiatry; 1989 Jan; 25(1):33-8. PubMed ID: 2643443
[TBL] [Abstract][Full Text] [Related]
20. A double-blind placebo-controlled comparison of phenelzine and imipramine in the treatment of bulimia in atypical depressives.
Rothschild R; Quitkin HM; Quitkin FM; Stewart JW; Ocepek-Welikson K; McGrath PJ; Tricamo E
Int J Eat Disord; 1994 Jan; 15(1):1-9. PubMed ID: 8124322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
